An interventional study of ECoG monitoring in Chronic Subdural Hematoma, sponsored by University of New Mexico. Withdrawn. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-05-01.
Sponsored by University of New Mexico · Not applicable, Interventional, and Diagnostic
Chronic subdural hematoma (cSDH) is one of the most common problems treated by neurosurgeons, particularly as the population ages. While often dismissed as a benign problem, it has become clear that cSDH is associated with worse long term functional and cognitive outcomes compared to matched controls. Though surgical techniques for treatment of cSDH are becoming more effective and safe, a persisting problem of fluctuating, stroke-like neurological deficits has re-emerged. Such deficits are not always directly related to hematoma mass effect and not always relieved with surgical decompression, but can result in prolonged hospital course, additional workup, and sometimes even additional invasive treatments. While the cause of such events is unknown, we recently documented for the first time that massive waves of spreading depolarization can occur in these patients and were closely linked to such neurologic deficits in some patients. In the current study, we plan to expand on these preliminary findings with rigorous, standardized application of post operative subdural electrocorticography monitoring, pioneered at our institution to detect SD. We also plan to build on our large retrospective analysis estimating the overall incidence of such deficits in cSDH patients by assessing multiple proposed risk factors for SD. In addition, for the first time, we will assess the short- and long-term consequences of cSDH and SD with detailed functional, cognitive, and headache related outcome measurement. These assessments are based on several remarkable cases we have observed with time-locked neurologic deterioration associated with recurrent SD. This study qualifies as a mechanistic clinical trial in that we will be prospectively assigning patients to the intervention of SD monitoring and assessing outcomes related to the occurrence of SD. This constitutes the application of a novel measure of brain signaling and assessing biomarkers of these physiologic processes of SD. These studies will provide critically needed information on this novel mechanism for neurologic deficits and worse outcomes after cSDH evacuation. Upon successful completion, we would identify a targetable mechanism for poor outcomes that occur commonly in patients with cSDH. This overall strategy offers the opportunity to radically improve the care of patients with cSDH by focusing on clinical trials of pharmacologic therapies for neurologic deficits in patients with cSDH.
112 studies on the registry are indexed under Hematoma, Subdural, Chronic; 49 are open to participants now.
Browse Hematoma, Subdural, Chronic studies →University of New Mexico is the lead sponsor of 313 studies on the registry; 29 are open to participants now.
Of its 25 completed or terminated interventional studies of FDA-regulated products, 23 (92%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients undergoing standard of care surgical evacuation of cSDH. will have subdural ECoG monitoring electrode placed crossing frontal and temporal lobes for 1-5 days of post operative monitoring. All subjects will undergo long term followup testing.
Diagnostic Test: ECoG monitoring
Brief (1-5 days) of post operative ECoG monitoring to detect spreading depolarization.
Post operative neurologic deterioration.
Incidence of decline in Markwalder grading scale (0\[normal\]-4\[comatose\]) or Glasgow coma scale (3\[no response\] to 15\[normal\]) by one point.
Time frame: 1-5 days
eGOS
Extended Glasgow outcome scale 1(dead)- 8(upper good recovery)
Time frame: 30day, 90 day, 180 day
MoCA
Montreal Cognitive Assessment (1-30) 30 is the best
Time frame: 30day, 90 day, 180 day
NIH toolbox cognitive battery
The NIH Toolbox Cognitive Battery provides an overall summary score along with fluid and crystallized cognition summary scores.
Time frame: 30day, 90 day, 180 day
PROMIS 29 profile
The PROMIS-29 v2.0 profile assesses pain intensity using a single 0-10 numeric rating item and seven health domains (physical function, fatigue, pain interference, depressive symptoms, anxiety, ability to participate in social roles and activities, and sleep disturbance) using four items per domain
Time frame: 30day, 90 day, 180 day
TBI QOL
The TBI-QOL consists of 20 independent calibrated item banks and 2 uncalibrated scales that measure physical, emotional, cognitive, and social aspects of health-related quality of life
Time frame: 30day, 90 day, 180 day
Headache disability Index
The Headache Disability Index (HDI) is a 27-item questionnaire.The first two questions asks the patient to identify the frequency (1 per month; more than 1 but less than 4 per month; more than 1 per week) and intensity (mild, moderate, severe) of their headache. The remaining questions evaluate quality of life issues to determine headache disability.
Time frame: 30day, 90 day, 180 day
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2025 to primary completion in Mar 2025, 0 months.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.